Trade Names:Chlorpropamide- Tablets 100 mg- Tablets 250 mgAPO-Chlorpropamide (Canada)
Decreases blood glucose by stimulating insulin release from pancreas.
Rapidly absorbed. T max is 2 to 4 h. C max is 30 mcg/mL.
Excreted in breast milk.
Metabolized in the liver.
The t ½ is about 36 h. 80% to 90% is excreted in urine within 96 h (as unchanged drug and as hydroxylated or hydrolyzed metabolites).
Within 1 h.
3 to 5 h.
24 to 60 h.
The t ½ is prolonged. Dosage adjustment may be needed.
Adjunct to diet to lower blood glucose in patients with non–insulin-dependent diabetes mellitus (type 2) whose hyperglycemia cannot be controlled by diet alone.
Control of neurogenic diabetes insipidus.
Hypersensitivity to sulfonylureas; diabetes complicated by ketoacidosis with or without coma; sole therapy for insulin-independent (type 1) diabetes mellitus; diabetes when complicated by pregnancy.
PO 250 mg/day in single dose.Elderly Initial dose
PO 100 to 125 mg/day in single dose.Maintenance
PO 100 to 250 mg/day in single dose.Severely Diabetic Adults
PO up to 500 mg/day; avoid doses above 750 mg/day.
Store in cool environment in tightly closed container.
May increase hypoglycemic effect.Beta-blockers, corticosteroids, diazoxide, hydantoins, rifampin, thiazide diuretics, urinary alkalinizers
May decrease hypoglycemic effect.
Drug causes elevated results.BUN and creatinine
Drug causes mild to moderate elevations.
Increased risk of CV mortality when compared with patients treated with diet alone.
Allergic skin reactions; eczema; pruritus; erythema; urticaria; morbilliform or maculopapular eruptions; lichenoid reactions; photosensitivity.
GI disturbances (eg, nausea, epigastric fullness, heartburn).
Leukopenia; thrombocytopenia; aplastic anemia; agranulocytosis; hemolytic anemia; pancytopenia; hepatic porphyria.
Cholestatic jaundice; elevated LFTs.
Hypoglycemia; SIADH with water retention and dilutional hyponatremia, especially in patients with CHF or hepatic cirrhosis.
Disulfiram-like reaction; weakness; paresthesia; fatigue; malaise.
Check blood sugar levels frequently and observe for symptoms of hypoglycemia or hyperglycemia and report to health care provider.
Category C . Insulin is recommended to maintain blood glucose levels during pregnancy. Prolonged severe neonatal hypoglycemia can occur if sulfonylureas are administered at time of delivery. If administering to pregnant patient, discontinue 2 days to 4 wk before expected date of delivery.
Excreted in breast milk.
Safety and efficacy not established.
Particularly susceptible to hypoglycemic action. Hypoglycemia can be difficult to recognize in elderly patients.
Use drug with caution and monitor renal function frequently.
Use drug with caution and monitor liver function frequently.
Particularly susceptible to hypoglycemic action.
A sulfonylurea-induced facial flushing reaction may occur when administered with alcohol.
When discontinuing chlorpropamide and switching to another oral hypoglycemic agent, exercise caution for 2 wk; prolonged action of chlorpropamide may provoke hypoglycemia.
Hypoglycemia, tingling of lips and tongue, hunger, nausea, lethargy, confusion, agitation, nervousness, tachycardia, sweating, tremor, convulsions, stupor, coma.
Copyright © 2009 Wolters Kluwer Health.